
CORRECTED VERSION

(19) World Intellectual Property Organization

International Bureau







PCT

(10) International Publication Number WO 2004/046160 A3

- (51) International Patent Classification⁷: A61K 31/7088, C07H 21/00
- (21) International Application Number:

PCT/DK2003/000788

(22) International Filing Date:

18 November 2003 (18.11.2003)

(25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: PA 2002 01774 18 November 2002 (18.11.2002) DK 20 October 2003 (20.10.2003) DK PA 2003 01540
- (71) Applicant (for all designated States except US): SAN-TARIS PHARMA A/S [DK/DK]; Bøge Allé 3, DK-2970 Hørsholm (DK).
- (72) Inventors; and
- (72) Inventors; and
 (75) Inventors/Applicants (for US only): CHRISTENSEN, Signe, M. [DK/DK]; Gammeltoftsgade 24, 3. Iv., DK-2200 Copenhagen N (DK). MIKKELSEN, Nikolaj, Dam [DK/DK]; Stenløsevej 52, DK-2700 Brønshøj (DK).

 FRIEDEN, Mirlam [DK/DK]; Rådmandsgade 15. 3. th., DK-Copenhagen N (DK). HANSEN, Henrik, Frydenlund [DK/DK]; Tärnvej 33 A. st., DK-2610 Rødovre (DK).

 KOCH, Troels [DK/DK]; Funkiavej 47, DK-2300 Copenhagen S. (DK). PEDERSEN, Daniel, Sejer [DK/GB]; Darwin College, Silver Street, Cambridge CB3 9EU (GB).

 ROSENBOHM, Christoph [DK/DK]; Kirsebærlunder 25, 3460 Birkerød (DK). THRUE, Charlotte, Albæk [DK/DK]; Kronprinsessegade 80 st., 1306 København K (DK). WESTERGAARD, Majken [DK/DK]; Ellebakken 5, DK-3460 Birkerød (DK).

 (54) Title: AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN

 (55) Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least on the properties of the properties of the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotides are composed of at least on the properties. The novel oligonucleotide

- (74) Agent: PLOUGMANN & VINGTOFT A/S; Sundkrogsdage 9, P.O. Box 831, DK-2100 Copenhagen Ø (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

